Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?
· fool.com · popularity 20/100 · 0 similar stories today · Corporate News & M&A (Business & Finance)
Read the original at fool.com →
Summary
Teva's three branded therapies of Austedo, Ajovy, and Uzedy brought in $1.1 billion in third-quarter revenue. Teva Pharmaceuticals (TEVA -0.17%) has …
Found in: The Motley Fool. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 5.